Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas

ACTON, Mass., January 2, 2024 Psychemedics Corporation, a global leader in hair testing for drugs of abuse, proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering exceptional service and maintaining the highest standards in hair drug testing. The move to Dallas underscores Psychemedics’ ... Read more

Psychemedics Corporation Appoints Daniella Mehalik as VP – Finance

ACTON, Mass., Nov. 27, 2023 -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of ... Read more

Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen

ACTON, Mass., Oct. 27, 2023 -- In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen. This groundbreaking offering will transform the way organizations safeguard their workplaces, shifting the spotlight from marijuana to ... Read more

Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

Acton, MA – [September 21, 2023] Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies. With an exceptional track record ... Read more

Psychemedics Corporation Welcomes Drew Reynolds To Its Board Of Directors And Announces The Retirement Of Harry Connick From His Director Role

Acton, Massachusetts, March 22, 2022 – Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, is pleased to welcome Andrew “Drew” M. Reynolds to the Psychemedics Board of Directors effective April 4th,2022.  Mr. Reynolds will also serve as a member of the Audit, Compensation, and Nominating and Governance Committees. Mr. ... Read more

Sarah Ashby Rejoins Psychemedics Corporation as Vice President, General Counsel

ACTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Sarah Ashby has rejoined the company as Vice President, General Counsel. In this important role, Sarah will be responsible for directing and managing all of the company’s legal activities. She will report directly to the company’s CEO. Sarah rejoins Psychemedics from ... Read more

Andrew Limbek Joins Psychemedics Corporation as Vice President, Controller

ACTON, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Andrew Limbek had joined the Company as Vice President, Controller. In this important role, Andrew will be responsible for directing and managing all of the Company’s financial activities, including external reporting and internal analysis. He will report directly to the Company’s ... Read more

Robyn C. Davis Joins Psychemedics Board of Directors

ACTON, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Robyn C. Davis was unanimously elected to serve on the Board of Directors of Psychemedics Corporation effective immediately. Ms. Davis will be filling the vacancy created by the untimely passing this past December of Clint Allen, a long-time and dedicated Psychemedics ... Read more

Psychemedics Announces a “Vaping Panel” to Detect and Deter the use of Marijuana, CBD and Nicotine

A New and Cost-Effective Tool to Combat the E-cigarette Epidemic Among Youth ACTON, MA, May 5, 2020 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced a Vaping Panel to detect the use of Marijuana, CBD and Nicotine. This test provides a … Read more

Psychemedics Test for Cotinine (metabolite of Nicotine) Detection Cleared by FDA

A New and Cost-Effective Tool to Detect and Deter Nicotine use ACTON, MA, April 29, 2020 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced the first FDA-cleared hair test for cotinine, the predominant metabolite for nicotine. This test provides a way … Read more